Tamoxifen Beyond Breast Cancer: Therapeutic Repurposing and Molecular Targets in Non-Mammary Malignancies

Glioblastoma multiforme displays pronounced intrinsic and acquired chemoresistance to temozolomide (TMZ), a barrier tamoxifen circumvents via non-classical estrogen receptor signaling ^[1][2]. Experimental models indicate that tamoxifen potentiates alkylating agent cytotoxicity and induces G1/S cell-cycle arrest in astrocytoma through direct antagonism of protein kinase C (PKC) ^[3][4]. This inhibition mirrors small-molecule PKC antagonists like Ro31-8220, stimulating p21(waf1/cip1) induction and retinoblastoma (Rb) protein dephosphorylation ^[4]. In pediatric and adult low-grade and high-grade gliomas, regimens incorporating tamoxifen at doses of 250 to 500 mg daily elevate serum and intracranial concentrations to micromolar thresholds needed to engage low-affinity non-ER targets ^[2][5][6]. He et al. demonstrated that tamoxifen administration sensitized temozolomide-resistant glioma cells to apoptosis by impairing intracellular prosurvival cascades ^[1]. In cellular models of chemoresistance, tamoxifen competitively binds and downregulates ATP-binding cassette transporter P-glycoprotein (P-gp), reversing multidrug-resistant phenotypes and enhancing alkylating drug accumulation ^[7]. Furthermore, tamoxifen crosses the blood-brain barrier to disrupt membrane trafficking, autophagy fluxes, and calcium homeostasis, exerting direct cytostatic suppression in neural and pituitary tumor lines independently of ERα status ^[2][8][9]. High-dose regimens achieved durable clinical disease control and 2-year survival metrics exceeding 60% when combined with standard cytostatics in neuro-oncology trials, confirming the clinical utility of targeting non-ER pathways in malignant brain tumors ^[2][5][6].

Therapy-induced senescence and genotoxic injury frequently provoke the generation of polyploid giant cancer cells (PGCCs), which evade cell cycle arrest and undergo amitotic budding to seed treatment-refractory recurrences and secondary malignancies ^[8]. White-Gilbertson et al. revealed that tamoxifen acts as a candidate first-in-class inhibitor of acid ceramidase (ASAH1), an essential regulator of sphingolipid turnover ^[8]. Pharmacological blockage of ASAH1 by tamoxifen perturbs the intracellular balance between pro-survival sphingosine-1-phosphate and pro-apoptotic ceramide, arresting the atypical amitotic division and progeny formation of PGCCs in therapy-resistant lesions ^[2][8]. This ASAH1 inhibition occurs at non-cytotoxic concentrations and functions independently of cellular ER expression ^[8]. In a nationwide cohort of patients with ductal carcinoma in situ receiving long-term tamoxifen, multivariate hazard evaluations demonstrated that the drug was not associated with an increased hazard of secondary non-breast primary malignancies (all-site HR = 1.014; 95% CI: 1.001–1.027), while controlling aberrant lineage expansions across colorectal, gastric, and bladder sites ^[10]. Off-target perturbation of lipid metabolic integrity by tamoxifen also impairs downstream prosurvival transcription factors, including peroxisome proliferator-activated receptor gamma (PPARγ) and NRF2 ^[2]. By repressing lipid desaturation and lysosomal catabolism in aberrant giant cells, tamoxifen curtails metastatic niche emergence and limits therapy-driven malignant progression across heterologous organ tissues ^[2][8][10].

Hematologic malignancies, including non-Hodgkin lymphomas, frequently exhibit distinct sex-steroid receptor landscapes characterized by high expression of estrogen receptor beta (ERβ) relative to ERα ^[11][12]. Langendonk et al. identified ERβ as a novel, druggable target in diffuse large B-cell lymphoma (DLBCL), showing that tamoxifen directly antagonizes ERβ signaling to suppress lymphoblast proliferation and trigger apoptotic cascades ^[11]. Pharmacological exposure to tamoxifen downregulates proto-oncogenic signaling networks, blocks cell motility, and triggers caspase-mediated cell death in both classical and histiocytic lymphoma models ^[1][11]. This ERβ blockade cooperates with downstream kinase modulation; tamoxifen simultaneously inhibits PKC isozymes and disrupts mitochondrial outer membrane potentials ^[4][11]. In addition, tamoxifen represses tumor vascularization in lymphoid microenvironments by decreasing systemic angiogenin levels and attenuating hypoxia-inducible factor (HIF) driven pro-angiogenic cascades ^[13][14]. Exogenous estrogenic stimulation, which accelerates lymphomagenesis in pre-clinical settings, is reversed upon tamoxifen administration, correlating with epidemiological observations of altered lymphoma risk following endocrine modulation ^[11][12]. In refractory hematologic models, tamoxifen also interferes with transmembrane transport by blocking multidrug resistance proteins, thereby enhancing intracellular drug retention and elevating responsiveness to multi-agent immuno-chemotherapy regimens ^[7][11][13].

Peritoneal carcinomatosis arising from gastric and colorectal neoplasms depends extensively on platelets and submesothelial stromal components to drive epithelial-mesenchymal transition (EMT) and metastatic colonization ^[7][15]. Wilson et al. showed that ex vivo pretreatment of normal platelets with tamoxifen markedly inhibits the release of platelet-derived growth factor (PDGF), transforming growth factor-beta 1 (TGF-β1), vascular endothelial growth factor (VEGF), and interleukin-6 (IL-6) ^[15]. Tamoxifen and its potent active metabolite 4-hydroxytamoxifen (4-OHT) attenuate platelet aggregation induced by adenosine diphosphate (ADP) and tumor cell interactions, abrogating cancer-platelet crosstalk ^[15]. Consequently, 4-OHT blocks the release of angiogenic mediators like angiogenin, chemokine CCL5, and matrix metalloproteinase 1 (MMP-1), while elevating angiopoietin-1 release to suppress neo-vascular sprouting ^[13][15]. Furthermore, tamoxifen directly inhibits megakaryocyte-expressed ERβ and androgens, reducing circulating platelet counts by up to 45% in vivo ^[15]. In human MKN-45 gastric carcinoma and colorectal metastasis assays, tamoxifen prevents the upregulation of mesenchymal transition markers, alters the Notch pathway, and restores cellular sensitivity to doxorubicin ^[7][15]. This anti-metastatic effect is reinforced by tamoxifen-mediated upregulation of TIMP-1 and simultaneous repression of MMP-9, severely retarding extracellular matrix degradation and the trans-mesothelial migration of circulating neoplastic cells ^[4][15].

Non-small cell lung cancer (NSCLC) cells frequently exhibit baseline or acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib, an obstacle overcome by dual receptor targeting ^[1][16]. Shen et al. confirmed that combining tamoxifen with gefitinib exerts marked synergistic antiproliferative effects in NSCLC by suppressing dual downstream signaling cascades ^[1]. Tamoxifen engages non-classical nuclear receptors, specifically ERβ, which is broadly expressed in lung adenocarcinomas and squamous cell carcinomas ^[12]. By inhibiting ERβ and suppressing EGFR phosphorylation simultaneously, tamoxifen blunts MAPK/ERK activation and diminishes cyclin D1 expression, enforcing persistent G0/G1 cell cycle arrest ^[4][17]. Concurrently, tamoxifen mitigates multi-drug resistance phenotypes in lung adenocarcinoma lines (such as SPC-A-1) through the up-regulation of TIMP-1 and the marked down-regulation of MMP-9, suppressing invasive cell migration and basement membrane extravasation ^[4]. In vivo murine lung tumor models show that tamoxifen diminishes absolute tumor volume and dampens vascular vessel density by reprogramming endothelial transcriptional responses ^[14]. Additionally, tamoxifen modulates the non-classical membrane receptor GPER, inducing autophagic flux and circumventing secondary cross-resistance ^[2][8]. High-dose schedules ranging from 300 to 500 mg daily have demonstrated manageable toxicities alongside enhanced efficacy when combined with targeted agents, highlighting tamoxifen as an effective partner for EGFR-directed lung cancer regimens ^[2][5].

Advanced and recurrent endometrial carcinoma (EC) represents a clinical challenge where hormonal strategies provide vital palliative efficacy ^[18][19]. In a systematic review by van Weelden et al., tamoxifen monotherapy yielded objective response rates (RRs) ranging between 10% and 53% in advanced EC, while alternate anti-estrogenic and SERD regimens showed response rates between 9% and 31% ^[18]. Despite tamoxifen's agonistic actions on resting endometrium—which drive a slight risk of secondary primary endometrial hyperplasia or uterine malignant mixed Müllerian tumors during chronic breast cancer prophylaxis—tamoxifen exerts robust antineoplastic antagonism in malignant endometrial epithelium ^{[17][18][19][20]}. When combined with progestins, tamoxifen acts by restoring and priming progesterone receptor (PR) expression, overcoming progestin receptor down-regulation and boosting combined therapeutic response rates up to 58% ^[18][21]. Simultaneous combination of anti-estrogens with mammalian target of rapamycin (mTOR) inhibitors achieved clinical benefit rates of 14% to 31%, countering survival cross-talk between the estrogen receptor and PI3K/Akt/mTOR pathways ^[18]. Furthermore, tamoxifen competitively displaces endogenous 17β-estradiol, reversing estradiol-induced endothelial cell proliferation and attenuating angiogenic signaling within endometrial tumor beds ^[13][14]. These endocrine interactions, supported by minimal adverse thrombotic and gastrointestinal toxicities, establish tamoxifen-progestin alternation as a benchmark approach in recurrent and hormone receptor-positive gynecologic cancers ^[18][22].

Follicular and papillary thyroid carcinoma lines frequently retain functional sex-steroid receptor signaling cascades, rendering their invasive phenotype susceptible to selective endocrine manipulation ^[1][4]. Hoelting et al. established that tamoxifen directly suppresses cellular growth, migration, and basement membrane invasion in both follicular and papillary thyroid cancers in vitro and in vivo ^[1]. This anti-invasive action operates predominantly through non-estrogen receptor mechanisms, as ER-negative thyroid neoplastic cells exhibit comparable sensitivity ^[1][4]. Specifically, tamoxifen treatment transcriptionally suppresses matrix metalloproteinase 9 (MMP-9) expression while concurrently elevating the metalloproteinase inhibitor TIMP-1, preventing proteolysis-dependent extracellular matrix remodeling ^[4]. Concurrently, tamoxifen impedes thyroid tumor vascular infiltration by disrupting angiogenin and VEGF synthesis in surrounding stromal and endothelial compartments ^[13][14]. Direct biophysical binding of tamoxifen to protein kinase C isoforms further induces p21(waf1/cip1) accumulation and Rb dephosphorylation, driving thyroid carcinoma cells into sustained cytostatic growth arrest ^[4]. Furthermore, tamoxifen-induced reactive oxygen species production and membrane lipid alterations promote programmed apoptotic cell death in undifferentiated thyroid carcinoma cells without damaging non-malignant endocrine tissue, highlighting its targeted anti-invasive efficacy in progressive endocrine cancers ^[4][23].

Desmoid fibromatosis (aggressive fibromatosis) is a locally destructive, non-metastasizing fibroblastic neoplasm driven by constitutive Wnt/β-catenin signaling pathway activation ^[6][17][22]. High-dose tamoxifen, routinely combined with non-steroidal anti-inflammatory drugs (NSAIDs) such as the non-selective cyclooxygenase inhibitor sulindac, yields objective tumor regressions and durable stable disease in patients with progressive, inoperable desmoid tumors ^[6][22]. Takebe et al. noted that high-dose SERM regimens induce partial regressions and disease stabilization in desmoid tumors, achieving clinical benefit rates exceeding 32% to 44% across dose-escalation cohorts ^[22]. Mechanistically, tamoxifen exerts cooperative anti-proliferative signaling with sulindac by modulating nuclear β-catenin translocation and blocking fibroblastic cell-cycle transitions ^[17][22]. The non-ER-dependent action of high-dose tamoxifen (reaching up to 250–500 mg daily) directly inhibits protein kinase C activity, limits extracellular matrix deposition, and halts local connective tissue infiltration ^[2][4][6]. In addition, tamoxifen suppresses platelet-derived transforming growth factor-beta 1 (TGF-β1) and PDGF release from associated stroma, disrupting the paracrine loops that sustain desmoid fibroblastic proliferation ^[15]. This therapeutic strategy stabilizes challenging anatomical sites, offering an effective systemic alternative to morbid surgical resections ^[6][22].

The clinical repurposing of tamoxifen in non-mammary oncology is underpinned by its capacity to modulate diverse non-ER molecular effectors at micromolar tissue concentrations ^[2][4][13]. Beyond nuclear receptors, tamoxifen acts as an inhibitor of protein kinase C (PKC), competing with diacylglycerol to suppress kinase activation, induce p21(waf1/cip1), and trigger G1 cell-cycle arrest in hepatocellular carcinoma, astrocytoma, and prostate cancer ^[1][4][23]. In vascular and tumor compartments, tamoxifen down-regulates angiogenin and VEGF production, reversing estradiol-stimulated endothelial proliferation and restricting tumor vessel network assembly ^[13][14]. Large-scale endothelial transcriptomics reveal that the active metabolite 4-OHT down-regulates 66% of estradiol-induced endothelial genes and modulates glycolytic cascades to arrest neoangiogenesis ^[14]. At the plasma membrane, tamoxifen binds to and inhibits the efflux pumps P-glycoprotein and multidrug resistance proteins, restoring intracellular chemotherapeutic drug levels in gastrointestinal and biliary tumors independent of ER expression ^[7][13]. Additionally, tamoxifen directly inhibits acid ceramidase (ASAH1), disrupting polyploid giant cancer cell (PGCC) division and eliminating resistant, blast-like progeny ^[8]. Together with GPER activation and the transcriptional induction of tissue inhibitor of metalloproteinases (TIMP-1), this complex non-ER pharmacology enables tamoxifen to bypass standard drug resistance and suppress solid tumor growth across multiple non-mammary malignancies ^{[2][4][8][12][13]}.